Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
Top Page
Personalis
(NASDAQ:PSNL)
51Neutral
Positive Factors
Partnerships
Moderna has signed a multi-year contract extension agreement with Personalis to use ImmunoID NeXT for clinical development of V940.
Product Demand
Strong demand seen for Personalis’ NeXT Personal testing product is a positive indicator for its future adoption.
Negative Factors
Revenue Projections
Revenues from the company’s client, Natera, may not be meaningful in 2025 as the relationship winds down.
Personalis (PSNL) vs. S&P 500 (SPY)
Market Cap
$316.42M
Dividend YieldN/A
Average Volume (3M)1.14M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth15.15%
EPS Growth39.27%
CountryUS
Employees225
SectorHealthcare
Sector Strength78
IndustryMedical Diagnostics & Screening
Share Statistics
EPS (TTM)-1.36
Shares Outstanding88,263,270
10 Day Avg. Volume1,272,380
30 Day Avg. Volume1,140,017
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.74
Price to Cash Flow (P/CF)-10.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.33Price Target Upside104.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Personalis Business Overview & Revenue Model
Company DescriptionPersonalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
How the Company Makes MoneyPersonalis generates revenue through its genomic sequencing and analytics services, which are offered primarily to biopharmaceutical companies, healthcare providers, and research institutions. The company provides comprehensive genomic profiling services, which help in drug development and personalized treatment plans by offering insights into the genetic makeup of tumors and other conditions. Key revenue streams include contracts for genomic testing services, partnerships with pharmaceutical companies for drug discovery and development, and collaborations with research institutions. Personalis also benefits from government grants and research funding, which contribute to its revenue. Strategic partnerships and collaborations play a significant role in expanding its service offerings and customer base.
Personalis Financial Statement Overview
Summary
Personalis shows revenue growth and improved gross margins, but persistent net losses, negative free cash flow, and limited profitability pose significant challenges. A strong balance sheet with low leverage and high liquidity provides a foundation for potential future growth.Income Statement
Personalis has shown revenue growth from 2023 to 2024 with a notable increase in total revenue by 15.16%. However, the company has consistently operated at a loss, with a negative net profit margin of -96.06% in 2024, although this is an improvement over the previous year. The gross profit margin has increased to 31.70%, indicating better cost management relative to revenue. Despite improvements, high operating losses reflected in negative EBIT and EBITDA margins suggest that the company still faces challenges in achieving profitability.55
Neutral
Balance Sheet
The balance sheet shows a strong equity position with an equity ratio of 75.09% in 2024, indicating financial stability. The debt-to-equity ratio is 0.22, reflecting low leverage and a conservative capital structure. However, the return on equity remains negative due to consistent net losses, suggesting that equity is not being effectively translated into profit. Positive cash and short-term investments further enhance liquidity but do not offset the profitability concerns.60
Neutral
Cash Flow
Personalis experienced a reduction in negative free cash flow from 2023 to 2024, showing some improvement in cash management. However, operating cash flow remains negative, and the free cash flow to net income ratio is unfavorable due to persistent losses. The operating cash flow to net income ratio suggests cash outflows are closely aligned with the net losses, indicating limited capacity to generate cash from core operations.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 84.61M | 73.48M | 65.05M | 85.49M | 78.65M | Gross Profit |
| 26.82M | 18.21M | 13.35M | 31.66M | 20.11M | EBIT |
| -68.27M | -109.94M | -115.53M | -65.35M | -42.15M | EBITDA |
| -70.30M | -96.81M | -104.64M | -59.01M | -34.05M | Net Income Common Stockholders |
| -81.28M | -108.30M | -113.31M | -65.23M | -41.28M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 185.01M | 114.18M | 167.66M | 287.06M | 203.29M | Total Assets |
| 270.27M | 225.10M | 292.70M | 396.53M | 244.84M | Total Debt |
| 44.25M | 48.96M | 48.65M | 52.80M | 10.99M | Net Debt |
| -47.17M | -8.02M | -40.48M | -52.79M | -57.54M | Total Liabilities |
| 67.31M | 95.66M | 74.56M | 86.23M | 49.90M | Stockholders Equity |
| 202.96M | 129.44M | 218.14M | 310.30M | 194.94M |
| Cash Flow | Free Cash Flow | |||
| -46.75M | -67.17M | -120.13M | -81.91M | -45.90M | Operating Cash Flow |
| -45.15M | -56.26M | -70.23M | -70.83M | -42.65M | Investing Cash Flow |
| -35.07M | 13.10M | 52.54M | -60.07M | -65.14M | Financing Cash Flow |
| 114.67M | 11.03M | 1.37M | 169.70M | 121.27M |
Personalis Technical Analysis
Negative
3.58
Price Trends
5.16
Negative
4.80
Negative
4.14
Negative
Market Momentum
-0.37
Positive
34.66
Neutral
22.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PSNL, the sentiment is Negative. The current price of 3.58 is below the 20-day moving average (MA) of 4.59, below the 50-day MA of 5.16, and below the 200-day MA of 4.14, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 34.66 is Neutral, neither overbought nor oversold. The STOCH value of 22.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PSNL.
Personalis Risk Analysis
Personalis disclosed 71 risk factors in its most recent earnings report. Personalis reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Personalis Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $8.52B | ― | -37.09% | ― | 10.37% | -389.98% | |
53 Neutral | $5.26B | ― | -4584.47% | ― | 31.04% | 16.91% | |
51 Neutral | $316.42M | ― | -48.91% | ― | 15.15% | 39.27% | |
51 Neutral | $537.97M | ― | -3.76% | ― | -1.99% | 74.89% | |
49 Neutral | $13.39B | ― | -30.11% | ― | -2.93% | -4.69% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
32 Underperform | $875.43M | ― | -54.14% | ― | ― | 6.99% |
* Healthcare Sector Average
Performance Comparison
PSNL
Personalis
3.82
2.13
126.04%
EXAS
Exact Sciences
46.35
-14.73
-24.12%
ILMN
Illumina
84.20
-44.84
-34.75%
RCKT
Rocket Pharmaceuticals
8.80
-19.36
-68.75%
FLGT
Fulgent Genetics
17.48
-5.57
-24.16%
GH
Guardant Health
43.10
24.10
126.84%
Personalis Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -15.57% | Next Earnings Date: Apr 30, 2025
Earnings Call Sentiment Neutral
The earnings call detailed positive developments such as significant revenue growth in biopharma, strategic partnerships, and progress in clinical test volumes and reimbursement submissions. However, it also noted challenges like a decrease in quarterly revenue, lower gross margin expectations for 2025, and an expected decline in revenue from Natera. The sentiment is balanced, with significant achievements tempered by notable challenges.Highlights
Full Year Revenue Growth
Personalis reported full year 2024 revenue of $84.6 million, a 15% increase over 2023, driven by a 60% year-over-year growth in biopharma.
Strong Partnership with Moderna
Extended a long-term agreement with Moderna to support ongoing clinical trials, expected to drive future revenue growth.
Significant Capital Raised
Raised approximately $115 million net in 2024 through strategic investments, including a $50 million investment from Merck.
Increased Clinical Test Volume
Personalis delivered 1,441 molecular tests in Q4, a 52% increase from the previous quarter.
Breast Cancer Submission for Medicare Reimbursement
Submitted for Medicare coverage for breast cancer testing, ahead of internal expectations.
Positive Physician Feedback
High retention of physicians using NeXT Personal, indicating satisfaction with the test.
Lowlights
Decrease in Quarterly Revenue
Q4 2024 revenue was $16.8 million, a 15% decrease compared to the same period in 2023, primarily due to lower volumes from Natera and the VA MVP.
Lower Gross Margin Guidance for 2025
2025 gross margin is expected to be 21% to 23%, lower than the 32% in 2024, due to unreimbursed test costs.
Expected Decline in Revenue from Natera
Anticipated a decline of about $20 million from Natera's business in 2025.
Net Loss for Full Year 2024
Reported a net loss of $81.3 million for 2024, though reduced from $108.3 million in 2023.
Company Guidance
During the Personalis Fourth Quarter 2024 Earnings Call, the company provided guidance for 2025, projecting total revenue in the range of $80 million to $90 million, despite an anticipated decline of about $20 million from Natera's business. They expect to grow their test volume by 30% to 40% each quarter until achieving reimbursement. In Q4 2024, they delivered 1,441 molecular tests, a 52% increase from the previous quarter, and reported a full year revenue of $84.6 million, up 15% from 2023. The biopharma segment grew 60% year-over-year, driven by clinical trial samples from Moderna. Cash usage for 2025 is projected at $75 million to $80 million, with a net loss of approximately $85 million, including $20 million of unreimbursed test costs. Gross margin is expected to be between 21% and 23%. The company aims to achieve Medicare reimbursement for at least two indications by the end of 2025.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.